Andrew J Cutler
Overview
Explore the profile of Andrew J Cutler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Masand P, McIntyre R, Cutler A, Ganz M, Lorden A, Patel K, et al.
Clin Ther
. 2023 Nov;
46(1):50-58.
PMID: 38036337
Purpose: Weight gain and associated negative cardiometabolic effects can occur as a result of mental illness or treatment with second-generation antipsychotics (SGAs), leading to increased rates of morbidity and mortality....
12.
Jain R, McIntyre R, Cutler A, Earley W, Nguyen H, Adams J, et al.
Int Clin Psychopharmacol
. 2023 Aug;
39(2):82-92.
PMID: 37551609
Post hoc analyses evaluated cariprazine, a dopamine D 3 -preferring D 3 /D 2 receptor partial agonist, in patients with bipolar I depression and high baseline anxiety. Data were pooled...
13.
Mattingly G, Childress A, Cutler A, Estrada J, Corliss M
Front Psychiatry
. 2023 Jul;
14:1193455.
PMID: 37426086
Introduction: Sleep-related problems are common in children with attention-deficit/hyperactivity disorder (ADHD). Sleep disorders are also side effects of all stimulant ADHD medications. Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a once-daily treatment approved for...
14.
Cutler A, Mattingly G, Maletic V
Transl Psychiatry
. 2023 Jun;
13(1):228.
PMID: 37365161
The pathophysiology of major depressive disorder (MDD) is thought to result from impaired connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key inhibitory neurotransmitter in the brain, working...
15.
Cutler A, Suzuki K, Starling B, Balakrishnan K, Komaroff M, Meeves S, et al.
J Child Adolesc Psychopharmacol
. 2023 Jun;
33(5):176-182.
PMID: 37339441
Amphetamines are a preferred treatment for attention-deficit/hyperactivity disorder (ADHD), with the dextroamphetamine transdermal system (d-ATS) providing an alternative to oral formulations. A pivotal trial of d-ATS in children and adolescents...
16.
Childress A, Cutler A, Patel M, Oh C
J Child Adolesc Psychopharmacol
. 2023 May;
33(4):134-142.
PMID: 37204277
Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A 12-month, open-label safety study with SDX/d-MPH in children with ADHD showed that SDX/d-MPH...
17.
Kantrowitz J, Correll C, Jain R, Cutler A
Int J Neuropsychopharmacol
. 2023 Mar;
26(5):322-330.
PMID: 36932673
Background: Schizophrenia is a disabling disorder that profoundly affects functioning and quality of life. While available antipsychotics have improved outcomes for patients with schizophrenia, they are relatively ineffective for negative...
18.
Tanner C, Caroff S, Cutler A, Lenderking W, Shalhoub H, Page V, et al.
J Patient Rep Outcomes
. 2023 Mar;
7(1):21.
PMID: 36892733
Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with antipsychotic use. Data from RE-KINECT, a real-world study of antipsychotic-treated outpatients, were analyzed to assess the...
19.
Childress A, Marraffino A, Cutler A, Oh C, Brams M
J Child Adolesc Psychopharmacol
. 2023 Feb;
33(2):51-58.
PMID: 36809150
Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A pivotal double-blind (DB) study of children aged 6-12 years with ADHD demonstrated efficacy...
20.
McIntyre R, Durgam S, Kozauer S, Chen R, Huo J, Davis R, et al.
Eur Neuropsychopharmacol
. 2023 Jan;
68:78-88.
PMID: 36640735
A recent Phase 3, randomized, double-blind, placebo-controlled study established that lumateperone 42-mg monotherapy significantly improved symptoms of depression in patients with bipolar depression. This manuscript reports prespecified secondary and post...